Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:18 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of BEZ235 as Monotherapy in Patients With Transitional Cell Carcinoma After Failure of Platinum Based Chemotherapy
NCT01856101 · Cliniques universitaires Saint-Luc- Université Catholique de Louvain · PHASE2 · terminated · last registry update 2019-04-10 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Novartis decided to stop the marketing of BEZ235” | – | Registry record, Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MTOR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-04-03Results posted on the registry: Masonic Cancer Center, University of Minnesota, Indoximod + Sipuleucel-T (NCT01560923)
- 2020-04-01Results posted on the registry: Millennium Pharmaceuticals, Inc., MLN0128 (NCT01058707)
- 2020-03-12Results posted on the registry: M.D. Anderson Cancer Center, TAK228 (NCT02727777)
- 2020-03-12Also stopped (terminated): M.D. Anderson Cancer Center, TAK228 (NCT02727777)
- 2020-03-12Also stopped (withdrawn): Gary Schwartz, TAK-228 + Letrozole (NCT02619669)
- 2020-03-03Results posted on the registry: Calithera Biosciences, Inc, Sapanisertib (NCT02197572)
- 2020-03-03Results posted on the registry: National Cancer Institute (NCI), Pazopanib + Pazopanib Hydrochloride (NCT02601209)
- 2020-02-28Results posted on the registry: Millennium Pharmaceuticals, Inc., Sapanisertib + Paclitaxel (NCT02412722)
- 2020-02-25Results posted on the registry: Millennium Pharmaceuticals, Inc., MLN2480 + MLN0128 (NCT02327169)
- 2020-01-27Results posted on the registry: Calithera Biosciences, Inc, Sapanisertib + Fulvestrant (NCT02049957)
- 2019-11-22Also stopped (withdrawn): Restorbio Inc., Dactolisib + Placebo (NCT04139915)
- 2019-10-30Results posted on the registry: Millennium Pharmaceuticals, Inc., TAK-228 + TAK-117 (NCT01899053)
- 2019-10-29Results posted on the registry: Memorial Sloan Kettering Cancer Center, MLN0128 (NCT02091531)
- 2019-10-25Phase 3 first posted: Restorbio Inc., Dactolisib + Placebo (NCT04139915)
- 2019-10-04Also stopped (terminated): University of Florida, Gedatolisib + Paclitaxel (NCT02920450)
- 2019-10-03Results posted on the registry: University of Florida, Gedatolisib + Paclitaxel (NCT02920450)
- 2019-08-08Results posted on the registry: Millennium Pharmaceuticals, Inc., MLN0128 + paclitaxel (NCT01351350)
- 2019-06-11Results posted on the registry: Sanofi, SAR245408 + SAR245409 (NCT01587040)
- 2019-05-20Also stopped (terminated): Samsung Medical Center, AZD2014 (NCT03061708)
- 2019-05-20Also stopped (withdrawn): Samsung Medical Center, Vistusertib(AZD2014) (NCT03166176)
- 2019-05-20Also stopped (terminated): Samsung Medical Center, AZD5363 + paclitaxel (NCT02449655)
- 2019-05-20Also stopped (withdrawn): Samsung Medical Center, Vistusertib(AZD2014) (NCT03166904)
- 2019-05-20Also stopped (terminated): Samsung Medical Center, AZD2014 (NCT03082833)
- 2019-05-06Results posted on the registry: Merck Sharp & Dohme LLC, Ridaforolimus 100 mg + Ridaforolimus 40 mg (NCT00874731)
- 2019-04-19Results posted on the registry: Merck Sharp & Dohme LLC, ridaforolimus (NCT01380184)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision